What Happened?
Shares of genomics company Illumina (NASDAQ: ILMN) fell 6.1% in the afternoon session as investors reacted to its second-quarter earnings report, where a year-over-year revenue decline overshadowed beats on profit and sales forecasts. The life sciences company reported that revenue fell 3% from the prior year, sparking concerns about its growth trajectory. Management pointed to challenges in the research market, citing uncertainty around National Institutes of Health (NIH) funding and ongoing export restrictions that limited sales in China. These company-specific issues were compounded by broader market fears over new tariffs and weak U.S. jobs data. While Illumina did raise its full-year profit guidance and announced the acquisition of SomaLogic, investors focused on the top-line revenue weakness.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Illumina? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Illumina’s shares are quite volatile and have had 19 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 4 days ago when the stock gained 3.7% on the news that analysts at Robert W. Baird increased their price target on the life sciences company's stock to $105.00. While the firm maintained its 'neutral' rating on the shares, the new price objective represented a significant increase from the previous target of $84.00. This analyst action followed Illumina's recent quarterly report, where the company posted earnings and revenue that narrowly beat Wall Street's consensus estimates. The life sciences company reported earnings per share of $0.97 and revenue of $1.04 billion. This performance, coupled with the revised price target, appeared to have bolstered investor confidence.
Illumina is down 25.8% since the beginning of the year, and at $97.11 per share, it is trading 37.4% below its 52-week high of $155.15 from November 2024. Investors who bought $1,000 worth of Illumina’s shares 5 years ago would now be looking at an investment worth $244.08.
Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
